Fermentation expert Dr. Brad Cox, who has been instrumental in developing F3’s cutting-edge capabilities, will lead the Euglena project at Algatech and support its fermentation activity.
Microalgae-derived ingredient specialists Algatech are to license the rights to the production of β-1,3-glucan from microalgae Euglena gracilis from US biotech firm F3 Platform Biologics.
The move seeks to bring better quality ß-1,3-glucans-based products to market 08 Aug 2019 --- Microalgae-derived ingredients player Algatech has licensed the rights and intellectual property related to the production of β-1,3-glucan from Euglena Gracilis
Paris, France — Solabia Group announced in a press release that it has acquired Algatech Ltd., which specializes in the development, cultivation and commercialization of ingredients delivered from microalgae for supplement, food and cosmetic brands.
TA Associates backed French pharmaceutical company Solabia Group has acquired Algatech for an undisclosed sum. Israel-based Algatech, founded in 1998, cultivates microalgae ingredients that are used by food supplements, food and cosmetics brands globally. [...]
Algatech is proud to announce its acquisition by French pharmaceutical company Solabia Group. We look forward to working with Solabia to drive innovation in the micro and macroalgae industries.